BioXcel Therapeutics Shares Rise after Positive FDA Feedback

BioXcel Therapeutics shares are trading higher after receiving positive FDA pre-sNDA meeting comments for their sNDA submission for BXCL501 in treating agitation associated with bipolar disorders or schizophrenia.